Esperion Offers Results Of Five Studies Of Heart DrugPlymouth-based Esperion Therapeutics Monday announced the results from a Phase 1 study and four preclinical studies for its heart disease drug candidate ETC-1002. Initial results look promising.
Esperion Starts Phase 2 Trial Of Cholesterol Buster
Best Winter Festivals In Metro Detroit
Thanksgiving Parade Guide

Watch & Listen